Methods for treatment of fabry disease
View Patent ↗Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
1. A method for treatment of Fabry disease in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective dose of 1-deoxygalactonojirimycin or a salt thereof, wherein the patient has an α-galactosidase A mutation selected from the group consisting of D244N, E59K, F113L, G144V, G183D, G328A, I91T, L32P, M284T, M296V, N263S, R363C, R363H, N34S, T41I, M51K, A97V, R112H, A143T, P205T, Y207S, N215S, P259R, N263S, L300P, E358A, P409A, S201F and F295C, and wherein the patient is administered about 150 mg of the 1-deoxygalactonojirimycin or salt thereof every other day.
2. The method of claim 1 , wherein the 1-deoxygalactonojirimycin or salt thereof enhances α-galactosidase A activity.
3. The method of claim 1 , wherein the patient is male.
4. The method of claim 1 , wherein the patient is female.
5. The method of claim 1 , wherein the mutation is D244N.
6. The method of claim 1 , wherein the mutation is E59K.
7. The method of claim 1 , wherein the mutation is F113L.
8. The method of claim 1 , wherein the mutation is G144V.
9. The method of claim 1 , wherein the mutation is G183D.
10. The method of claim 1 , wherein the mutation is G328A.
11. The method of claim 1 , wherein the mutation is I91T.
12. The method of claim 1 , wherein the mutation is L32P.
13. The method of claim 1 , wherein the mutation is M284T.
14. The method of claim 1 , wherein the mutation is M296V.
15. The method of claim 1 , wherein the mutation is N263S.
16. The method of claim 1 , wherein the mutation is R363C.
17. The method of claim 1 , wherein the mutation is R363H.
18. The method of claim 1 , wherein the mutation is N34S.
19. The method of claim 1 , wherein the mutation is T41I.
20. The method of claim 1 , wherein the mutation is M51K.
21. The method of claim 1 , wherein the mutation is A97V.
22. The method of claim 1 , wherein the mutation is R112H.
23. The method of claim 1 , wherein the mutation is A143T.
24. The method of claim 1 , wherein the mutation is P205T.
25. The method of claim 1 , wherein the mutation is Y207S.
26. The method of claim 1 , wherein the mutation is N215S.
27. The method of claim 1 , wherein the mutation is P259R.
28. The method of claim 1 , wherein the mutation is N263S.
29. The method of claim 1 , wherein the mutation is L300P.
30. The method of claim 1 , wherein the mutation is E358A.
31. The method of claim 1 , wherein the mutation is P409A.
32. The method of claim 1 , wherein the mutation is S201F.
33. The method of claim 1 , wherein the mutation is F295C.